Artiva Biotherapeutics Return on Equity (ROE) Growth & History (ARTV)
Artiva Biotherapeutics's return on equity was −56.55% for fiscal 2025.
View full Artiva Biotherapeutics company overviewArtiva Biotherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −56.55% | +474.38 pp |
| 2024 | 2024-12-31 | −530.93% | — |
Artiva Biotherapeutics quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −11.49% | +1.89 pp |
| Q1 2026 | 2026-03-31 | −23.78% | −12.35 pp |
| Q4 2025 | 2025-12-31 | −17.37% | −9.06 pp |
| Q3 2025 | 2025-09-30 | −15.47% | +337.53 pp |
| Q2 2025 | 2025-06-30 | −13.37% | — |
| Q1 2025 | 2025-03-31 | −11.43% | — |
| Q4 2024 | 2024-12-31 | −8.30% | — |
| Q3 2024 | 2024-09-30 | −353.01% | — |
Artiva Biotherapeutics return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Artiva Biotherapeutics's return on equity increased from −530.93% to −56.55%, a change of +474.38 percentage points. The latest reported quarter, Q2 2026, shows −11.49%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Artiva Biotherapeutics source filings ↗